| cannabidiol |
drug |
3 |
3 |
CBD |
| cannabinoids |
drug |
17 |
10 |
THC, cannabinoid receptors, cannabinoids, delta-9-tetrahydrocannabinol, endogenous cannabinoid, marijuana, natural cannabinoids, naturally occurring cannabinoids, synthetic cannabinoids |
| cannabis dependence |
phenotype |
45 |
26 |
CAD symptoms, CD, CUD, CaD, Cannabis abuse, Cannabis dependence, DSM-IV cannabis dependence, DSM‑IV cannabis abuse/dependence, abuse, abuse/dependence, cannabis abuse, cannabis abuse/dependence, cannabis abusers, cannabis dependence, cannabis dependence criteria, cannabis dependence symptom, cannabis dependence symptomatology, cannabis dependence symptoms, cannabis dependence syndrome, cannabis dependent cases, cannabis involvement, cannabis misuse, cannabis problem use, cannabis problems, cannabis symptoms, cannabis use disorder, cannabis use problems, cannabis-dependent, cannabis-dependent outpatients, cannabis-related problems, cannabis-use disorder, dependence, dependence symptoms, impaired control, marijuana dependence, psychological dependence |
| cannabis initiation |
phenotype |
10 |
8 |
age of cannabis initiation, cannabis initiation, cannabis initiation before age 15, cannabis involvement, cannabis use initiation, cannabis use onset |
| cannabis-related problems |
phenotype |
5 |
5 |
cannabis outcomes, cannabis problems, cannabis use behaviors, cannabis use problems, cannabis-related problems, early adolescent cannabis use problems, later adolescent cannabis use problems, negative consequences, negative consequences of cannabis use, problem use, social or health problems |
| cannabis use |
phenotype |
106 |
66 |
Cannabis, Cannabis ever use, Cannabis sativa, Cannabis use, Exogenous cannabis, Marijuana, THC, active cannabis, adolescent cannabis use, adolescent-onset cannabis use, adolescent-onset of cannabis use, any cannabis use, cannabinoid exposure, cannabis, cannabis abuse, cannabis cigarette, cannabis consumption, cannabis ever use, cannabis exposure, cannabis initiation, cannabis involvement, cannabis misuse, cannabis problem use, cannabis products, cannabis smoking, cannabis use, cannabis use behavior, cannabis use problems, cannabis users, cannabis using group, casual cannabis use, chronic cannabis exposure, chronic cannabis use, ever cannabis use, ever having used cannabis, ever use of cannabis, ever used, ever used cannabis, ever using cannabis, frequency of use, frequent cannabis use, hashish, heavy cannabis use, heavy cannabis users, initiate cannabis use, initiation, initiation of cannabis use, lifetime cannabis use, lifetime history of cannabis use, marihuana, marijuana, marijuana cigarettes, marijuana use, medical marijuana, placebo cannabis, potent forms of cannabis, probability of cannabis use, problem cannabis use, repeated cannabis use, smoked cannabis, tetrahydrocannabinol, weed, weekly cannabis use |
| cannabis use disorder |
phenotype |
40 |
30 |
CAD, CUD, CUD diagnosis, CUD severity, CUDs, Cannabis Use Disorder (CUD), DSM-5 CUD symptom counts, DSM-5 cannabis use disorder, DSM-IV CUD symptom counts, abuse or dependence, cannabis, cannabis abuse, cannabis abuse/dependence, cannabis dependence, cannabis disorder, cannabis use disorder, cannabis use disorders, ongoing CUD |
| Cannabis use onset |
phenotype |
2 |
— |
first use of cannabis, onset of cannabis use |
| Cannabis use PRS |
phenotype |
2 |
2 |
PRS, cannabis PRS, cannabis use polygenic risk score, polygenic risk score for cannabis use |
| cannabis users |
phenotype |
5 |
4 |
active cannabis users, adolescent chronic cannabis users, adult chronic cannabis users, cannabis users, chronic cannabis use, chronic cannabis users, chronic marijuana use, early chronic cannabis use, heavy cannabis users, long-term cannabis use, long-term heavy cannabis users |
| cannabis withdrawal |
phenotype |
4 |
4 |
CWS, Cannabis withdrawal, Cannabis withdrawal symptoms, cannabis withdrawal, cannabis withdrawal symptoms, cannabis withdrawal syndrome, withdrawal, withdrawal from cannabis, withdrawal symptoms, withdrawal symptoms of cannabis |
| capsaicin |
drug |
2 |
1 |
|
| CAR |
gene |
2 |
2 |
NR1I3, androstane receptor, constitutive androstane receptor |
| carbachol |
drug |
2 |
2 |
|
| carbamazepine |
drug |
3 |
3 |
Tegretol, carbamezepine |
| carbon monoxide |
drug |
5 |
3 |
CO, baseline CO, expired CO |
| CARDIA |
cohort |
2 |
— |
Coronary Artery Risk Development in Young Adults |
| cardiomyopathy |
phenotype |
5 |
1 |
|
| cardiovascular disease |
phenotype |
59 |
31 |
CVD, CVDs, Cardiovascular, cardio vascular disease, cardiovascular disease, cardiovascular diseases, heart conditions, heart disease |
| cardiovascular events |
phenotype |
2 |
1 |
CVD events |
